Simcere Pharmaceutical Group
http://en.simcere.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Simcere Pharmaceutical Group
China Biotech Podcast: BIOSECURE Act Updates ASCO Highlights
US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.
ASCO: Simcere Targets Suvemcitug OS Win In Platinum-Resistant Ovarian Cancer
In a late-breaker oral presentation at ASCO on the SCORES study with suvemcitug, Simcere revealed a trend favoring an overall survival advantage in platinum-resistant oral cancer, despite immature data.
Chinese Drug Makers Trim, Boost Pipelines In New R&D Drive
The ranks of B7-H3-targeting antibody-drug conjugates under development in China have seen their first dropout, although elsewhere there are two FGFR2b-directed ADCs with first-in-class potential on the horizon. Meanwhile, there have been other discontinuations of KRAS G12C inhibitors and anti-BCMA CAR-T cell therapies in the country, while new players have surfaced in the areas of mRNA cancer vaccines and amyloid-beta-targeting antibodies for Alzheimer’s disease.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Jilin Boda Pharmaceutical Co., Ltd.
- ChinaVax
- Master Luck Corporation Limited
- Jiangsu Simcere Pharmaceutical R&D Co., Ltd.
- Jiangsu Yanshen Biological Technology Stock Co., Ltd.
- Nanjing Tung Chit Pharmaceutical Co., Ltd.
- Shandong Simcere Medgenn Bio-Pharmaceutical Co. Ltd.
- Wuhu Zhong Ren Pharmaceutical Co. Ltd.
- Xiangao Investment Company Ltd.
- Yantai Medgenn Co. Ltd.
- Jiangsu Simcere Pharmaceutical Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice